Boryeong Launches 'Lavetrix', a Combination of Aspirin and Rabeprazole
Reducing the Risk of Gastrointestinal Bleeding in Patients Taking Aspirin
Boryung Co., Ltd. announced on the 18th that it has launched 'Rabetrix Capsule,' a combination drug of 'Aspirin' and 'Rabeprazole.'
Rabetrix is a product that improves gastrointestinal bleeding that may occur when taking aspirin through rabeprazole. Aspirin, an antiplatelet agent, is used for the treatment and prevention of diseases caused by thrombosis. However, it is known that the risk of gastrointestinal bleeding increases by about 40% when taking aspirin, leading many patients at risk of gastrointestinal bleeding such as gastric ulcers to discontinue treatment prematurely.
On the other hand, rabeprazole, when administered together with aspirin, can reduce the recurrence rate of gastric ulcers and improve damage to the gastric and duodenal mucosa. Rabetrix, which combines these two components, is prescribed to patients who require aspirin administration but are at risk of gastrointestinal bleeding. It enhances convenience by allowing once-daily dosing compared to taking the drugs separately, and the drug price has also become more affordable.
Aspirin carries a risk of gastrointestinal bleeding, making pre-meal administration difficult, but Rabetrix compensates for this drawback with an 'enteric-coated capsule' technology that dissolves in the intestines rather than the stomach. Additionally, by utilizing the 'Polycap' formulation, different ingredient tablets are contained within one capsule, maintaining their individual release patterns and minimizing interference.
Boryung possesses sales and marketing know-how in the cardiovascular market based on the new antihypertensive drug 'Kanab Family,' and plans to strengthen its position in the market by expanding its cardiovascular disease portfolio to include antiplatelet and anticoagulant agents with the launch of Rabetrix.
Hot Picks Today
If They Fail Next Year, Bonus Drops to 97 Million Won... A Closer Look at Samsung Electronics DS Division’s 600M vs 460M vs 160M Performance Bonuses
- Opening a Bank Account in Korea Is Too Difficult..."Over 150,000 Won in Notarization Fees Just for a Child's Account and Debit Card" [Foreigner K-Finance Status]②
- "While Others Rest, Nearly 3 Million May Work Substitute Public Holidays Without Extra Pay"
- Lived as Family for Over 30 Years... Daughter-in-Law Cast Aside After Husband's Death
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
Kim Young-seok, CE Division Head of Boryung, said, "Rabetrix is a product that not only prevents the risk of gastrointestinal bleeding that may occur when taking aspirin but also offers convenience in administration and an economical drug price. We will continue to focus on securing competitiveness in the market by consistently launching excellent pharmaceuticals that can expand treatment options in the cardiovascular field."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
